Oncothyreon Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright
In a research note released today, H.C. Wainwright analyst Reni Benjamin reiterated a Buy rating on Oncothyreon (NASDAQ:ONTY) with a $4 price target, following the company’s release of its third-quarter results.
Benjamin noted, “Oncothyreon has several value driving therapeutics in clinical development including ONT-380, a potent and highly specific tyrosine kinase inhibitor targeting HER2, as well as ONT-10, an immunotherapy vaccine targeting MUC1. Additionally, the company’s acquisition of Alpine Biosciences brings a novel drug-delivery platform in-house, which we believe could be utilized to generate multiple therapeutic candidates in a wide variety of indications. Given the company’s burgeoning pipeline, ability to secure partnerships and strong cash position of approximately $91.2 MM, we believe Oncothyreon represents an undervalued player with significant upside for the long-term investor.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Reni Benjamin has a total average return of -2.6% and a 35.5% success rate. Benjamin has a -12.1% average return when recommending ONTY, and is ranked #2964 out of 3382 analysts.